Use of cannabinoids in the treatment of epilepsy
The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
1. A method of treating seizures in a patient with Doose Syndrome, comprising administering to the patient a pharmaceutical composition comprising a cannabidiol (CBD) drug substance, wherein the drug substance is at least 95% (w/w) CBD, and the CBD is administered at a dose ranging from about 5 mg/kg/day to about 25 mg/kg/day.
2. The method of claim 1 , wherein the drug substance is least 98% (w/w) CBD.
3. The method of claim 1 , wherein the CBD drug substance comprises Δ9-tetrahydrocannabinol (THC).
4. The method of claim 3 , wherein the CBD drug substance comprises two or more of THC, cannabidiolic acid (CBDA), cannabidivarian (CBDV), or CBD-C4.
5. The method of claim 1 , wherein the dose of the CBD is about 10 mg/kg/day.
6. The method of claim 1 , wherein the dose of the CBD is about 20 mg/kg/day.
7. The method of claim 1 , wherein the dose of the CBD is about 25 mg/kg/day.
8. The method of claim 2 , wherein the dose of the CBD is about 10 mg/kg/day.
9. The method of claim 2 , wherein the dose of the CBD is about 20 mg/kg/day.
10. The method of claim 2 , wherein the dose of the CBD is about 25 mg/kg/day.
11. The method of claim 1 , wherein the seizures are atonic seizures, tonic, clonic, tonic-clonic seizures, absence seizures, or myoclonic seizures.
12. The method of claim 5 , wherein the administering reduces the number of atonic seizures, tonic-clonic seizures, absence seizures, or myoclonic seizures.
13. The method of claim 6 , wherein the administering reduces the number of atonic seizures, tonic-clonic seizures, absence seizures, or myoclonic seizures.
14. The method of claim 7 , wherein the administering reduces the number of atonic seizures, tonic-clonic seizures, absence seizures, or myoclonic seizures.
15. The method of claim 8 , wherein the administering reduces the number of atonic seizures, tonic-clonic seizures, absence seizures, or myoclonic seizures.
16. The method of claim 9 , wherein the administering reduces the number of atonic seizures, tonic-clonic seizures, absence seizures, or myoclonic seizures.
17. The method of claim 10 , wherein the administering reduces the number of atonic seizures, tonic-clonic seizures, absence seizures, or myoclonic seizures.
18. The method of claim 1 , wherein the number of seizures are reduced by at least 50% compared to the number of seizures experienced during a baseline period before CBD was administered.
19. The method of claim 11 , wherein the number of seizures are reduced by at least 50% compared to the number of seizures experienced during a baseline period before CBD was administered.
20. The method of claim 12 , wherein the number of seizures are reduced by at least 50% compared to the number of seizures experienced during a baseline period before CBD was administered.
21. The method of claim 13 , wherein the number of seizures are reduced by at least 50% compared to the number of seizures experienced during a baseline period before CBD was administered.
22. The method of claim 14 , wherein the number of seizures are reduced by at least 50% compared to the number of seizures experienced during a baseline period before CBD was administered.
23. The method of claim 15 , wherein the number of seizures are reduced by at least 50% compared to the number of seizures experienced during a baseline period before CBD was administered.
24. The method of claim 16 , wherein the number of seizures are reduced by at least 50% compared to the number of seizures experienced during a baseline period before CBD was administered.
25. The method of claim 17 , wherein the number of seizures are reduced by at least 50% compared to the number of seizures experienced during a baseline period before CBD was administered.
26. The method of claim 1 , wherein the pharmaceutical formulation is an oral solution comprising one or more excipients.